11:42 Fri 06 Dec 2019
Alliance Pharma PLC - Grant of Options to Directors
For immediate release |
|
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Grant of Options to Directors
The share options awarded under the 2015 Company Share Option Plan have all been granted with an exercise price of 76.9p, being the closing mid-market price on 4th
The vesting of these awards is subject to continued employment and the satisfaction of performance conditions based on EPS and TSR targets.
The net effect of the grant of Share Options and the resultant option holdings are shown in the table below:
|
Share Options granted |
Total no. of options over ordinary shares now held |
|
334,184 |
2,989,184 |
|
206,183 |
1,609,183 |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by person discharging managerial responsibilities.
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
a) |
|
Mr |
|
2 |
Reason for the notification |
||
a) |
Position/status |
Chief Executive Officer - PDMR |
|
b) |
Initial notification /Amendment |
Initial Notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
a) |
|
|
|
b) |
Legal Entity Identifier |
N/A |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of
ISIN: GB0031030819 |
|
b) |
Nature of the transaction |
Grant of Options |
|
c) |
Currency |
GBP |
|
d) |
Price(s) and volume(s) |
Exercise Price (p) |
No. of share options |
76.9p |
137,500 |
||
Nil |
196,684 |
||
|
|||
e) |
Aggregated information - Aggregated volume - Price - Aggregated total |
Grant of 137,500 options to acquire shares at Grant of 196,684 options to acquire shares at nil-cost.
|
|
f) |
Date of the transaction |
|
|
g) |
Place of the transaction |
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
a) |
|
Mr |
|
2 |
Reason for the notification |
||
a) |
Position/status |
Chief Financial Officer - PDMR |
|
b) |
Initial notification /Amendment |
Initial Notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
a) |
|
|
|
b) |
Legal Entity Identifier |
N/A |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of
ISIN: GB0031030819 |
|
b) |
Nature of the transaction |
Grant of Options |
|
c) |
Currency |
GBP |
|
d) |
Price(s) and volume(s) |
Exercise Price (p) |
No. of share options |
76.9p |
95,000 |
||
Nil |
111,183 |
||
|
|||
e) |
Aggregated information - Aggregated volume - Price - Aggregated total |
Grant of 95,000 options to acquire shares at Grant of 111,183 options to acquire shares at nil-cost.
|
|
f) |
Date of the transaction |
|
|
g) |
Place of the transaction |
|
For further information:
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
Buchanan + 44 (0) 20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Freddie Barnfield, Huw Jeremy
Corporate Broking: James Black
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE